Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11652653 | 0.87 | CA1 (0.33) | CA2CA1CA9 | |
| SCHEMBL4611122 | 0.79 | CA2 (0.31) | CA2CA1CA9 | |
| SCHEMBL349256 | 0.79 | FDPS (0.38) | CA2CA1CA9CA4CA6 | |
| SCHEMBL6843768 | 0.77 | FDPS (0.37) | CA2CA1CA9CA4CA6 | |
| SCHEMBL7463702 | 0.77 | FDPS (0.37) | CA2CA1CA9CA4CA6 | |
| SCHEMBL9460150 | 0.77 | CA2 (0.37) | CA2CA1CA9TSHRTDP1 | |
| SCHEMBL17456411 | 0.75 | CA1 (0.48) | CA2CA1CA9 | |
| Ammonia Solution, Strong SCHEMBL9460243 | 0.74 | CA2 (0.35) | CA2TSHRTDP1 | |
| Methylamine SCHEMBL28902819 | 0.74 | CA2 (0.31) | CA2CA1CA9 | |
| SCHEMBL1889753 | 0.72 | CA2 (0.33) | CA2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | CA2 153/4885CA1 340/4885CA9 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.